Company profile
AlveoliX AG company profile
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs. AlveoliX aims at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing.
Business identity
- Website
- http://www.alveolix.com
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $50,000+
- Founded
- 2019-01-01, Year
Headquarters
- Headquarters
- Bulle, Fribourg, Switzerland
- Postal code
- 3010
- Country code
- CH
- Continent
- Europe